

# Pathology-MRI Correlation of Hepatocarcinogenesis: Recent Update

Jimi Huh<sup>1</sup> · Kyung Won Kim<sup>1,2</sup>  
Jihun Kim<sup>2,3</sup> · Eunsil Yu<sup>2,3</sup>

<sup>1</sup>Department of Radiology, <sup>2</sup>Asan Liver Center,  
<sup>3</sup>Department of Pathology, Asan Medical Center,  
University of Ulsan College of Medicine,  
Seoul, Korea

Received: April 7, 2015  
Accepted: April 14, 2015

## Corresponding Author

Kyung Won Kim, M.D., Ph.D.  
Department of Radiology, Asan Medical Center,  
University of Ulsan College of Medicine,  
88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736,  
Korea  
Tel: +82-2-3010-4377  
Fax: +82-2-3010-8724  
E-mail: medimash@gmail.com

Understanding the important alterations during hepatocarcinogenesis as well as the characteristic magnetic resonance imaging (MRI) and histopathological features will be helpful for managing patients with chronic liver disease and hepatocellular carcinoma. Recent advances in MRI techniques, such as fat/iron quantification, diffusion-weighted images, and gadoteric acid-enhanced MRI, have greatly enhanced our understanding of hepatocarcinogenesis.

**Key Words:** Hepatocarcinogenesis; Magnetic resonance image; Carcinoma, hepatocellular; Pathology


Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of death from cancer.<sup>1</sup> Asia is an endemic area of HCC. It is estimated that approximately 75%–80% of the HCC cases worldwide develop in Asia.<sup>2</sup> The primary etiological factor in Asia is the hepatitis B virus; however, the proportion of hepatitis C virus–related HCC has been increasing.<sup>3</sup> In chronic hepatitis B or C, multistep hepatocarcinogenesis, in which dysplastic nodules progress to early HCC and eventually advanced HCC, is widely accepted as the main mechanism of HCC development.<sup>4</sup>

Knowledge of the mechanism of hepatocarcinogenesis is important, as it may contribute to improved detection of HCC at an early stage and more successful therapeutic outcomes. In fact, the 5-year survival rate for patients with HCC has improved over the past several decades, and the early detection of HCC is one of the most important contributing factors.<sup>5</sup> In particular, the nationwide surveillance for HCC among high-risk individuals has allowed small HCCs less than 2 cm in diameter to be easily detected.<sup>4</sup> Furthermore, the rapid development of noninvasive imaging technology, including the rapidly developing, high-quality magnetic resonance (MR) techniques using new, cell-specific contrast agents, may allow further improvement of

the detection and characterization of small nodules in cirrhotic livers.<sup>6</sup> As a result, we are currently able to diagnose more early-stage HCCs. Pathologists and radiologists should be aware of the variable imaging features of these early-stage HCCs, as they frequently show different characteristics than advanced HCC. In this study, we review the important changes in magnetic resonance imaging (MRI) and histopathologic features during multistep hepatocarcinogenesis as well as the recent developments in MRI technology for detecting and characterizing hepatocellular nodules.

## MULTISTEP HEPATOCARCINOGENESIS: HISTOLOGIC CHANGE

Multistep hepatocarcinogenesis is characterized by progressive dedifferentiation of phenotypically abnormal nodular lesions in the liver and the emergence of successively more advanced precancerous, early cancerous, and overtly cancerous lesions (Fig. 1).<sup>7,8</sup> Chronic inflammation causes repeated injury to liver cells and regeneration of injured tissue, both of which promote accumulation of genetic and epigenetic alterations.<sup>9-12</sup> These alterations begin from the early preneoplastic phase and progress par-



**Fig. 1.** Schematic view of multistep hepatocarcinogenesis. Unpaired arterial supply replaces portal supply progressively from regenerative nodules to progressed hepatocellular carcinoma (yellow, nodules with portal supply; red, nodules with unpaired arterial supply). Degrees of various pathologic components are depicted as gradient bars. DN, dysplastic nodule; HCC, hepatocellular carcinoma; HG, high grade; LG, low grade; RN, regenerative nodule.

allel to the evolution of hepatic fibrosis or cirrhosis.<sup>13,14</sup>

This linear, repetitive, and successive process of the expansion and development of less differentiated, aberrant clonal populations of hepatocytes causes their evolution over time.<sup>15</sup> These dedifferentiated clonal populations eventually completely replace those of the more differentiated environment. Repetitive clonal growth and expansion ultimately generates nodules of the malignant phenotype. The dedifferentiated evolution process occurs in serial order as a biologic continuum *in vivo*; however, these processes are divided into discrete steps for clinical use.<sup>16</sup>

In 1995, after the stepwise development of HCC from regenerating nodules of liver cirrhosis was proposed, the International Working Party (IWP) of the World Congress of Gastroenterology defined regenerative nodules (RNs), low-grade dysplastic nodules (DNs), high-grade DNs, and HCC as steps from regeneration to cancer.<sup>17,18</sup> In addition, the IWP defined small HCCs as tumors less than 2 cm in diameter. However, there had been debate regarding the definition of small HCC, as these tumors can be divided into early HCCs, i.e., an early stage of hepatocarcinogenesis, and progressed HCCs, i.e., advanced HCC less than 2 cm in diameter. In addition, the accurate pathological definition of early HCCs differentiated from DNs was not established until recently. Finally, in 2009 the International Consensus Group for Hepatocellular Neoplasia (ICGHN) reached a consensus regarding the pathological criteria of early HCCs, as discussed below.<sup>19</sup> These international efforts have contributed greatly to the standardization of the nomenclature regarding

nodules during hepatocarcinogenesis.

### Regenerative nodules


A RN, also known as a cirrhotic nodule, is a well-defined nodular region surrounded by fibrotic/scar tissue, which has emerged from the regenerative process of the injured liver tissue. In RNs, the cells are histologically normal and lack clonal features.<sup>18</sup> A RN is considered a benign hepatocellular nodule.

### Dysplastic nodules

DNs are small nodules which are in the precancerous stage between benign RNs and malignant HCC. DN usually differ from the surrounding liver parenchyma in color, texture, and cellular change.<sup>18</sup> DN is subdivided into low-grade DN and high-grade DN.

Low-grade DN shows features suggestive of a clonal cell population without significant architectural or cellular atypia (Fig. 2A). Occasionally, low-grade DN demonstrates large cell change, although they do not show small cell change. Low-grade DN can show a mild increase in cell density with a monotonous pattern. A nodule-in-nodule pattern is not present in low-grade DN.<sup>18,20</sup>

In contrast, high-grade DN shows cytological and architectural atypia, although those changes are insufficient for a diagnosis of malignancy.<sup>18</sup> Small cell change is the most frequently seen cytological atypia. The architectural atypia observed in high-grade DN includes the thick cell plates up to three cells thick and/or pseudoglandular structures (Fig. 2B). The cell den-



**Fig. 2.** Representative pathologic images of multistep hepatocarcinogenesis. (A) Low-grade dysplastic nodule (right of the dashed line) shows increased cellularity, and residual portal tracts (arrow) are easily identifiable within the nodule. (B) High-grade dysplastic nodule (left of the dashed line) shows further increased cellularity and frequent unpaired arteries (arrow). (C) Early hepatocellular carcinoma (below the dashed line) is poorly demarcated but shows unequivocal cytological atypia and stromal invasion (arrow). (D) Advanced hepatocellular carcinoma is well demarcated by a thick capsule and shows overt features of malignancy.

sity of these lesions is usually 1.3–2 times greater than that of the adjacent cirrhotic parenchyma.<sup>19</sup>

### Early HCC

In 2009, the ICGHN made a consensus for the definition of early HCC.<sup>19</sup> Early HCCs are considered “*in situ* carcinoma” showing well-differentiated proliferation.<sup>18,20</sup> Early HCCs are referred to as ‘small HCC of the vaguely nodular type.’ The most important histologic feature that distinguishes early HCCs from high-grade DN is stromal invasion, defined as the presence of tumor cells invading the portal tracts or fibrous septa (Fig. 2C). Early HCCs also show various combinations of the following histologic features: “(1) increased cell density more than two times that of the surrounding liver parenchyma and with an increased nuclear/cytoplasm ratio and irregular, thin trabecular pattern; (2) varying numbers of portal tracts within the nodule (intratumoral portal tracts); (3) a pseudoglandular

pattern; (4) diffuse fatty change; and (5) various numbers of unpaired arteries.”<sup>19</sup>

There may be confusion regarding the terminology of early HCC and small HCC. By the definition of the IWP consensus in 1995, small HCC is a tumor less than 2 cm, whereas early HCC refers to well-differentiated HCC of the vaguely nodular type during the hepatocarcinogenesis process. The question has remained for small HCCs with moderate or poor differentiation. After much debate, such tumors are now termed “small progressed HCC” or “small HCC of the distinctively nodular type.” In Table 1, the terminology and histologic characteristics of these small, hepatocellular lesions are summarized.

### Progressed HCC

Progressed HCCs are overtly malignant hepatocellular lesions. Small lesions with a maximum diameter less than 2 cm usually have distinctly nodular macroscopic features,<sup>19</sup> while

**Table 1.** Terminology and histologic characteristics of these small (less than 2 cm) hepatocellular lesions

Terminology	Feature	Histologic characteristic
Regenerative nodules	Gross	Well-defined rounded regions of the cirrhotic parenchyma surrounded by scar tissue
	Microscopic	Phenotypically normal cells
Dysplastic nodules	Gross	Distinctly nodular lesions which differ from adjacent cirrhotic parenchyma with regard to size, color, texture, and degree of bulging at the cut surface
	Microscopic	Divided into low-grade DNs and high-grade DNs – Low-grade DN: a clonal cell population without significant architectural atypia and with a mild increase in cell density – High-grade DN: a clonal cell population with cytological and architectural atypia although not sufficient for a diagnosis of malignancy
Early HCCs (=small HCCs of the vaguely nodular type)	Gross	Vaguely nodular lesions with indistinct margins
	Microscopic	Well-differentiated histology of HCC with increased cell density and an irregular, thin-trabecular pattern; the stromal invasion is the most helpful feature to differentiate early HCC from high-grade DN
Progressed HCCs (=small HCCs of the distinctly nodular type)	Gross	Distinctly nodular lesions
	Microscopic	Well (G1) to moderately (G2) differentiated histology of HCC

DN, dysplastic nodule; HCC, hepatocellular carcinoma.

large lesions greater than 2 cm in diameter, which are termed “large HCCs,” have variable macroscopic features. Although three common macroscopic patterns of large HCCs have been proposed,<sup>21</sup> six macroscopic patterns, which were proposed by the Korean Liver Cancer Study Group, are more widely accepted in Korea.<sup>22</sup> Briefly, expanding nodular pattern is defined by one single, dominant mass and is the most common type. In these tumors, mosaic architecture is frequently observed, characterized by the multiple sub-nodules separated by fibrous septations and foci of hemorrhage or necrosis.<sup>23</sup> Nodular and perinodular extension type and infiltrative pattern show a dominant mass with infiltration into adjacent hepatic parenchyma along < 50% of tumor border in the former and ≥ 50% in the latter. Those tumors are usually associated with poorly differentiated cancer cells that spread into the surrounding sinusoids and cell plates.<sup>17,24</sup> Cirrhotomimetic pattern represents widespread infiltration by innumerable small nodules that frequently replace the whole liver.<sup>21</sup> In addition, multinodular confluent type and pedunculated type have also been described.<sup>22</sup> These progressed HCCs with both small and large lesions frequently show macroscopic vascular invasion with involvement of portal veins and less frequently hepatic veins. Sometimes, bile duct invasion may be seen macroscopically.

On histology, the main hallmark of HCC is that the malignant cells resemble the normal liver, both in architecture and cytology. Progressed HCCs can show different degrees of hepatocellular differentiation ranging from well-differentiated to poorly differentiated. Based on the degree of nuclear anaplasia, the Edmondson and Steiner system was proposed and is widely used to divide HCC into four grades from I to IV.<sup>17,25</sup> The common histologic patterns include (1) trabecular pattern, where tumor

cells with hepatocellular differentiation are arranged in plates of various thickness, separated by sinusoid vascular spaces (Fig. 2D); (2) pseudoglandular pattern, where gland-like dilatation of the canaliculi are present between tumor cells forming the lumen; (3) compact pattern, which is composed of thick trabeculae compressed into a compact mass; (4) scirrhous pattern, where desmoplastic stroma divides tumor cell masses into smaller nests; and (5) fibrolamellar pattern, which shows characteristic lamellar collagen bundles running between large glassy tumor cells.

## RECENT ADVANCES IN MAGNETIC RESONANCE IMAGING TECHNIQUES

Recently, the diagnosis of hepatocellular carcinoma has become primarily based on imaging.<sup>26</sup> In clinical practice, computed tomography (CT) is the most widely used imaging modality to diagnose HCC. With the dramatic technical advances in MRI, it is currently more useful than other imaging modalities for diagnosing HCC because it provides better soft-tissue contrast and information regarding cellularity, tissue components, and hemodynamic changes of the hepatocellular nodules. In the recent past, the spatial resolution and scan speed were generally better on CT than on MRI,<sup>27,28</sup> however, recently developed MRI units have fast scanning with high spatial resolution, comparable to CT scanning. Therefore, the use of MRI for the diagnosis of HCC has greatly increased.

Nonradiologist physicians may not be familiar with MRI sequences and the information that can be obtained from those sequences. Indeed, there are many sequences of liver MRI which may cause confusion. In addition, the interpretation of MRI largely depends on which contrast agent is used. We summarize

the commonly used sequences in Table 2 and illustrate the representative images of such sequences in Fig. 3.

### T2-weighted images

T2-weighted imaging (T2-WI) highlights the differences in the T2 relaxation time of tissues. Sequences for T2-WI are the


basic components of MRI, and are quite helpful for the differential diagnosis of liver tumors. For example, hepatic cysts and hemangiomas show very high T2 hyperintensity, while HCCs show intermediately high T2 hyperintensity (Fig. 3A).<sup>29</sup>

For routine liver MRI, two kinds of T2-WI sequences are used: sequences moderately weighting T2, including fast spin-


**Table 2.** Commonly used MRI sequences for liver imaging

MRI sequences	Information
T2-weighted images	Helpful for differential diagnosis Hepatic cysts and hemangiomas show very high T2 hyperintensity, while HCCs show intermediately high T2 hyperintensity
T1-weighted dual gradient-echo images (in-phase and opposed-phase)	Helpful for detecting the intralobular fat component
Multiphasic dynamic imaging (arterial phase, portal-venous phase, and three-minute equilibrium phase)	Evaluate the hemodynamic pattern of hepatic tumors HCCs typically show arterial enhancement and delayed washout
Hepatobiliary phase imaging (i.e., 20-minute delayed image)	When gadoxetic acid is used as a contrast agent, the hepatobiliary phase is used to improve the detection and characterization of hepatocellular nodules
Diffusion-weighted imaging	Helpful for the detection and characterization of hepatocellular nodules

MRI, magnetic resonance imaging; HCC, hepatocellular carcinoma.



**Fig. 3.** Routine magnetic resonance imaging sequences. (A) T2-weighted imaging is helpful for the differential diagnosis of liver tumors. Hepatocellular carcinoma (HCC) usually shows intermediate high-signal intensity (arrowheads on the left), whereas hepatic cysts show bright high-signal intensity (arrow on the right). (B) In-phase and opposed-phase images provide information regarding the fat or iron content of hepatocellular nodules. The fat component of a nodule is seen as high-signal intensity on in-phase imaging (arrowhead on the left) and as low-signal intensity on opposed-phase imaging (arrow on the middle). On histology of the resected specimen, the nodule is confirmed as a fat-containing HCC.  
(Continued to the next page)



**Fig. 3.** (Continued) (C) Multiphasic dynamic images and hepatobiliary-phase images. After contrast injection, T1-weighted images are obtained in the arterial phase (AP), portal-venous phase (PVP), three-minute, delayed equilibrium phase (EP), and 20-minute, delayed hepatobiliary phase (HBP) to provide hemodynamic information regarding liver tumors. An HCC (arrowheads) shows typical hemodynamic features, including enhancement on AP, and washout on PVP and EP. On HBP, the HCC is seen as a hypodense mass. (D) Diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) map are helpful for evaluating the cellularity of a liver tumor. HCC mostly shows high signal intensity on DWI (arrow on the left) and low signal on the ADC map (arrowheads on the right).

echo or turbo spin-echo, and sequences exaggerating T2 of tissues, including single-shot fast spin-echo or half-Fourier acquisition single-shot turbo spin-echo.<sup>29</sup>

#### T1-weighted, dual gradient-echo sequence (in-phase and opposed-phase)

A T1-weighted, dual gradient-echo sequence is composed of

an in-phase image and an opposed-phase image. These images are routine components of the liver MRI protocol, as they can evaluate the fat content of tissues.<sup>30</sup> They are primarily used to identify diffuse or focal hepatic steatosis or to detect the fatty component of liver tumors, such as fat-containing, dysplastic nodules or HCC. When comparing the signal intensity (SI) between in-phase and opposed-phase images, the fatty component

of tissue shows a signal drop in the opposed-phase (Fig. 3B).

This sequence is also helpful for detecting the iron component of tissues using the dual-echo approach. In contrast to the fatty component, the iron component shows a signal drop on in-phase images compared to opposed-phase images. Therefore, the pathological conditions, such as hemochromatosis or hemosiderosis, can be identified.<sup>7</sup> It is also helpful to detect iron-containing liver tumors, such as siderotic nodules or iron-containing hepatocellular lesions.

### Multiphasic dynamic imaging

In liver MRI, contrast agents have crucial roles in the detection and characterization of HCC, based on evaluation of the hemodynamic pattern of liver tumors and liver parenchyma. Multiphasic dynamic imaging consists of repeated acquisition of T1-weighted images (T1-WIs) after contrast agent injection and is composed of the arterial phase, portal-venous phase, and three minutes of the equilibrium phase (Fig. 3C). Enhancement in the arterial phase and washout in the portal or equilibrium phase is regarded as a characteristic feature of HCC on both dynamic CT and dynamic MRI.<sup>31</sup>

### Hepatobiliary phase images

The hepatobiliary phase refers to a 20-minute delayed phase following injection of gadoteric acid (Fig. 3C). Therefore, the hepatobiliary phase is only performed when gadoteric acid is used as the contrast agent. Gadoteric acid is a dual-function agent allowing both dynamic imaging and hepatobiliary-phase imaging. It has characteristics like extracellular contrast agents and can be used in dynamic MRI within three minutes after contrast agent injection. In the hepatobiliary phase, gadoteric acid is taken up by cells that express the OATP receptor. Normal hepatocytes usually express abundant OATP receptors, while HCCs or liver metastases lack OATP receptors. This results in improved lesion-to-liver contrast because normal liver parenchyma shows high SI while liver tumors show dark SI in the hepatobiliary phase of gadoteric-acid-enhanced MRI.<sup>32</sup>

Gadoteric acid is excreted into the biliary system. In the hepatobiliary phase it is possible to observe the biliary excretion of gadoteric acid, which thus allows functional biliary imaging. In liver tissue in which the bile duct is obstructed, biliary excretion is not observed. Regarding liver tumor evaluation, the hepatobiliary phase is sometimes helpful for obtaining a differential diagnosis. For example, focal nodular hyperplasia (FNH) has a functioning, hepatocyte-expressing OATP receptor, although it has no biliary excretion system. Therefore, gadoteric acid is re-

tained for a long time within an FNH nodule. FNH shows high SI in the hepatobiliary phase, which is helpful for differentiating FNH from HCC.<sup>8</sup>

### Diffusion-weighted imaging

Diffusion-weighted imaging is a sequence to map the diffusion process of molecules, primarily water molecules, in biological tissues. Diffusion is a random motion of water molecules. In tissues or cells, diffusion of water molecules is restricted due to the interactions of molecules.<sup>33</sup> The degree of diffusion restriction varies across tissues, thus reflecting the microscopic details of biological tissues. The apparent diffusion coefficient (ADC) is a quantitative parameter of diffusion restriction calculated from diffusion-weighted images. The ADC map, together with diffusion-weighted images, is quite helpful for visual assessment and quantitative analysis of a liver tumor (Fig. 3D).

The diffusion of water molecules is highly restricted in dense cellular tissue such as HCC, compared to that of normal liver parenchyma, whereas necrosis or nonviable tumor tissues cause increased membranous permeability allowing free diffusion of water molecules.<sup>34</sup> Therefore, diffusion-weighted images are helpful for detecting highly cellular tumors and for differentiating malignant lesions from benign lesions.

## MAGNETIC RESONANCE IMAGING OF ALTERATIONS DURING HEPATOCARCINOGENESIS

During multistep hepatocarcinogenesis, the important changes in hepatocellular nodules are neo-angiogenesis, cellular differentiation and density, fat or iron accumulation, and biliary drainage dysfunction (Fig. 1). Recent advances in MR technology allow the evaluation of these pathological and functional changes.<sup>6,35</sup>

### Alteration of hepatic vasculature

During hepatocarcinogenesis, hemodynamic change occurs in hepatocellular nodules and can be visualized by radiologic imaging and histopathology.<sup>36</sup> The blood flow of RNs is supplied from both the portal vein (75%–80%) and the hepatic artery (20%–25%), as with normal liver parenchyma. As the hepatocellular nodules evolve from low-grade DN through high-grade DN to early HCC, both the intranodular portal blood supply and the hepatic arterial blood supply tend to decrease.<sup>37</sup> The majority of these nodules are still hypovascular on dynamic MRI.<sup>9</sup> As the grade of HCCs increases, i.e., Edmondson grade II or

greater, the intranodular portal supply definitely decreases, whereas the intranodular arterial supply tends to progressively increase. This increased intranodular arterial input is due to neo-angiogenesis of the unpaired artery in the lesion.<sup>10</sup> Therefore, the majority of advanced HCCs show typical hemodynamic features of arterial enhancement and portal/delayed washout (Fig. 3C).

### Cellular change in hepatocellular nodules

As hepatocellular nodules evolve from DN to HCCs, several cellular changes occur, including small cell change, increased cell density, and nodule-in-nodule growth. These cellular changes can be detected in T2-WI and diffusion-weighted images.<sup>55</sup>

First, cell density can be evaluated by diffusion-weighted imaging and T2-WI. Low-grade DN show a mild increase in cell density, and high-grade DN show a moderate increase in cell density, i.e., as much as twice that of the surrounding liver parenchyma.<sup>11</sup> However, these cellular changes of DN are usually insufficient to show overt high SI on diffusion-weighted images and T2-WI. In contrast, in HCCs, an increase in cell density is usually sufficiently detectable on diffusion-weighted images or T2-WIs.<sup>38</sup> Small cell change is frequently observed in HCC and may also contribute to diffusion restriction of water molecules in the malignant cells seen on diffusion-weighted images (Fig. 3D).

Secondly, the nodule-in-nodule pattern is one of the typical histologic and imaging features of HCC, although it is uncommon. Usually, cirrhotic nodules and low-grade DN are seen as distinct single nodules, while some high-grade DN contain sub-nodules which are usually HCC foci, i.e., clones of malignant-transformed cells from DN during hepatocarcinogenesis. The nodule-in-nodule pattern can be depicted by either T2-WI


or dynamic MRI.<sup>39</sup> If the sub-nodule within the DN shows arterial enhancement, it is easily detected in the arterial phase of dynamic MRI (Fig. 4).

Thirdly, the tumor capsule is a characteristic feature of progressed HCCs.<sup>39</sup> It is usually seen as a thin rim of low SI on non-contrast T1-WI. On contrast-enhanced MRI, the tumor capsule can be progressively enhanced following injection of gadolinium contrast agent, as the tumor capsule is generally composed of fibrous tissue containing compressed vessels (Fig. 5).<sup>12</sup> On T2-WI, the tumor capsule may show variable SI as either low SI or high SI. Although the tumor capsule is regarded as a characteristic finding of progressed HCCs, it may be present in large DN and may not be seen in small HCCs. For the diagnosis of HCC, the presence of a tumor capsule is helpful, although not essential.

### Alterations of the fat/iron composition in hepatocellular nodules

During hepatocarcinogenesis, iron may accumulate in low-grade DN and in some high-grade DN. These nodules containing an iron deposit are referred to as 'siderotic nodules' (Fig. 6). In hepatocytes of siderotic nodules, the iron-transporter system, such as the transferrin transporter, are upregulated.<sup>14</sup> However, as these nodules progress into HCCs, the iron-transportation system also alters, and iron utilization increases, thus causing iron deficiency in HCCs.<sup>15</sup> Therefore, with progression to HCC, iron usually decreases.

These alterations of the fat composition in DN and HCCs are often helpful for characterizing hepatocellular nodules on MRI. On T2-WI or T2\*-WI, the iron component is seen as



**Fig. 4.** Nodule-in-nodule pattern of hepatocellular carcinoma (HCC). On a multiphasic, dynamic magnetic resonance imaging of a 50-year-old patient with HCC, there is a large mass without arterial hypervascularity (arrowheads on the left) and a sub-nodule with strong arterial hypervascularity (asterisk on the left) on the arterial-phase image, i.e., the so-called nodule-in-nodule pattern. The central sub-nodule shows washout on the portal-venous phase (asterisk in the middle). After the patient was treated with transarterial chemoembolization, lipiodol was taken up only in the sub-nodule (asterisk on the right). These findings suggest the presence of HCC as a sub-nodule arising from a large dysplastic nodule.



dark SI. On T1-weighted, dual gradient-echo images, the iron component shows a signal drop in in-phase images compared to that of opposed-phase images. Iron-containing, hepatocellular nodules are usually DNs and are unlikely to be HCCs. The development of an iron-deficient sub-nodule within a siderotic nodule indicates HCC foci arising from the DN. Likewise, if a siderotic nodule is seen to be iron-free on a follow-up study, it may suggest its transformation into HCC.<sup>17</sup>


Fat accumulation within hepatocellular nodules is also altered during hepatocarcinogenesis. In low-grade DNs, high-grade DNs, and early HCCs, fat can accumulate focally or diffusely in the nodules. The intralesional fat accumulation peaks in the early HCC stage and regresses according to the increasing size and grade of HCCs. Usually, poorly differentiated HCCs or large HCCs > 3 cm rarely show intralesional fat accumulation.<sup>13</sup> The fat component can be evaluated on T1-weighted, dual gradient-

echo images. The fatty component of tissue shows a signal drop in opposed-phase images compared to in-phase images (Fig. 3B).


## MAGNETIC RESONANCE IMAGING FINDINGS OF HEPATOCARCINOGENESIS

### Regenerative nodules

On MRI, most RNs are imperceptible and isointense on un-enhanced T1-WIs and T2-WIs. Some of these nodules may be differentiated by unusual imaging features, such as hyperintensity on T1-WIs and hypointensity on T2-WIs. When enhanced with contrast material, most RNs demonstrate a similar degree of enhancement with that of the adjacent parenchyma, although occasionally mild, delayed-phase hypoenhancement or hepatobiliary phase hyperintensity may be seen.<sup>27,40</sup>



**Fig. 5.** Tumor capsule of the hepatocellular carcinoma (HCC). The tumor capsule (arrowheads) is seen as a hypointense rim on the arterial-phase (AP) image (left) and as an enhancing rim on the portal-venous phase (PVP) image (middle), indicating a delayed and persistent enhancement pattern. On T2-weighted imaging (T2-WI), the tumor capsule is seen as a hyperintense rim (right).



**Fig. 6.** Siderotic nodule. A 60-year-old patient with liver cirrhosis underwent liver magnetic resonance imaging. On in-phase images, there are many nodules with low signal intensity (arrowheads on the left), which are not clearly demonstrable on opposed-phase images (right). This signal drop of nodules on the in-phase image suggests that these nodules contain an iron component (so-called siderotic nodules).

### Dysplastic nodules

Common imaging findings of DN are hyperintensity on T1-WIs and isointensity or hypointensity on T2-WIs.<sup>27,41</sup> The T1 hyperintensity can be explained by the fact that DN accumulate copper or iron, which are paramagnetic materials leading to T1 hyperintensity depending on the concentration. Such intranodular copper or iron accumulation may lead to T2 hypointensity due to the T2-shortening effects. Some DN, especially high-grade DN, may show fatty change manifested as T1 hyperintensity on MRI.

After contrast agent injection, most DN are usually isointense to the liver parenchyma in the hepatic arterial, portal venous, and hepatobiliary phases. As some DN show washout or capsular enhancement in the delayed phase and hypointensity in the hepatobiliary phase, these findings may be good predictors of pre-malignancy.<sup>27</sup>

### Early HCC


Most early HCCs are either isointense or hyperintense on T1-WIs and are mostly isointense on T2-WIs.<sup>42</sup> In addition, most

early HCCs are hypovascular, and only 5% of the early HCCs show arterial hypervascularity on dynamic MRI. These characteristics are nonspecific, suggesting that it is difficult to accurately diagnose early HCC using conventional MRI.

In particular, differentiating early HCC from high-grade DN on MRI is quite challenging. There are a few differential points. First, high SI on diffusion-weighted images almost always indicates early HCC. DN are almost never hyperintense on T2-WI and diffusion-weighted images.<sup>17</sup> Second, nodule hypointensity on the hepatobiliary phase of gadoteric-acid-enhanced MRI favors early HCC rather than high-grade DN, as a substantial number of such hypointense nodules show hypervascularity during the follow-up period (Fig. 7).<sup>43</sup>

### Progressed HCC

The typical MRI findings of HCC, which have been extensively investigated in numerous research studies, mostly apply to progressed HCC rather than early HCC. The hallmarks of HCC are arterial hypervascularity and washout on the portal-venous phase and/or equilibrium phase of multiphasic dynamic



**Fig. 7.** A 65-year-old patient with a liver nodule. (A) On the initial magnetic resonance imaging (MRI), there is a 1.4 cm, hypointense nodule on the portal-venous phase (PVP, arrowhead) without arterial hypervascularity (arrow) on the arterial phase (AP). This nodule was regarded as a high-grade dysplastic nodule or early hepatocellular carcinoma (HCC). (B) On the one-year follow-up MRI, the nodule had increased in size. The nodule showed hypointensity on the hepatobiliary phase (HBP, arrowheads) and arterial hypervascularity on the AP (arrow), which suggests development of HCC.

CT or MRI.<sup>4,37</sup> This finding is due to the predominant vascular supply to HCCs from unpaired hepatic arteries and the absence of the portal vein supply. These hemodynamic changes are apparent in the progressed HCC rather than the early HCC. Therefore, it is very helpful to differentiate small progressed HCC from early HCC. In addition, the nodule margin seen on MRI is also helpful to differentiate small, progressed HCC, because it is more distinctly nodular than early HCC with its indistinct margin. Indeed, the tumor capsule is a characteristic feature of progressed HCCs and is seen as a persistent enhancing rim at the periphery of the tumor.<sup>39</sup>

Progressed HCCs can present as infiltrative masses as well as expansile nodules/masses. In infiltrative masses, the tumor cells may infiltrate through the tumor capsule into the surrounding parenchyma.<sup>17</sup> These infiltrative HCCs frequently show vascular invasion or biliary invasion, thus leading to a poor patient prognosis.

Vascular invasion is common in progressed HCCs, including portal vein invasion or hepatic vein invasion. As vascular invasion is rarely observed in other types of liver malignancies, this is a helpful characteristic for diagnosing HCC. Vascular invasion generally indicates a poor prognosis for the patients, as it is a route of tumor spread through the liver and of systemic metastasis.<sup>26</sup>

## CONCLUSION

The incidence of small HCCs has recently been increasing due to a nationwide surveillance program and advances in imaging techniques. It is difficult to correctly diagnose such small HCCs during histological and radiological examinations. Understanding the important alterations during hepatocarcinogenesis as well as the characteristic MRI and histopathological features will be helpful for managing patients with chronic liver disease and HCC. There is no doubt that special MRI techniques, such as fat/iron quantification, diffusion-weighted images, and gadoteric-acid-enhanced MRI, have greatly enhanced our understanding of hepatocarcinogenesis.

### Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

### Acknowledgments

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry

Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant No. HI14C1090).

## REFERENCES

1. Song P, Tang W, Tamura S, *et al.* The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation. *Biosci Trends* 2010; 4: 283-7.
2. Kudo M, Han KH, Kokudo N, *et al.* Liver Cancer Working Group report. *Jpn J Clin Oncol* 2010; 40 Suppl 1: i19-27.
3. Lee SH, Choi HC, Jeong SH, *et al.* Hepatocellular carcinoma in older adults: clinical features, treatments, and survival. *J Am Geriatr Soc* 2011; 59: 241-50.
4. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. *J Gastroenterol* 2009; 44 Suppl 19: 112-8.
5. Yoo HJ, Lee JM, Lee MW, *et al.* Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0T-MR imaging with pathologic correlation. *Invest Radiol* 2008; 43: 538-46.
6. Choi BI, Lee JM. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: imaging diagnosis and staging of hepatocellular carcinoma. *J Hepatobiliary Pancreat Sci* 2010; 17: 369-73.
7. Henninger B, Zoller H, Rauch S, *et al.* Automated two-point dixon screening for the evaluation of hepatic steatosis and siderosis: comparison with R2\*-relaxometry and chemical shift-based sequences. *Eur Radiol* 2015; 25: 1356-65.
8. Suh CH, Kim KW, Kim GY, Shin YM, Kim PN, Park SH. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. *Eur Radiol* 2015; 25: 950-60.
9. Krinsky G. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers. *Intervirology* 2004; 47: 191-8.
10. Fournier LS, Cuenod CA, de Bazelaire C, *et al.* Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent. *Eur Radiol* 2004; 14: 2125-33.
11. Roncalli M, Terracciano L, Di Tommaso L, *et al.* Liver precancerous lesions and hepatocellular carcinoma: the histology report. *Dig Liver Dis* 2011; 43 Suppl 4: S361-72.
12. Ishigami K, Yoshimitsu K, Nishihara Y, *et al.* Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. *Radiology* 2009; 250: 435-43.
13. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. *J Hepatol* 2000; 33: 282-9.

14. Pascale RM, De Miglio MR, Muroi MR, *et al.* Transferrin and transferrin receptor gene expression and iron uptake in hepatocellular carcinoma in the rat. *Hepatology* 1998; 27: 452-61.
15. Holmstrom P, Gåfvels M, Eriksson LC, *et al.* Expression of iron regulatory genes in a rat model of hepatocellular carcinoma. *Liver Int* 2006; 26: 976-85.
16. Libbrecht L, Craninx M, Nevens F, Desmet V, Roskams T. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. *Histopathology* 2001; 39: 66-73.
17. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. *Radiology* 2014; 272: 635-54.
18. International Working Party. Terminology of nodular hepatocellular lesions. *Hepatology* 1995; 22: 983-93.
19. International Consensus Group for Hepatocellular Neoplasia; The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. *Hepatology* 2009; 49: 658-64.
20. Park YN. Update on precursor and early lesions of hepatocellular carcinomas. *Arch Pathol Lab Med* 2011; 135: 704-15.
21. Okuda K, Peters RL, Simson IW. Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas: proposal of new classification. *Cancer* 1984; 54: 2165-73.
22. Korean Liver Cancer Study Group. Pathology for prediction of liver. General rules for the study of primary liver cancer. Seoul: Korean Liver Cancer Study Group, 2004; 39-40.
23. Choi BI, Lee GK, Kim ST, Han MC. Mosaic pattern of encapsulated hepatocellular carcinoma: correlation of magnetic resonance imaging and pathology. *Gastrointest Radiol* 1990; 15: 238-40.
24. Demirjian A, Peng P, Geschwind JF, *et al.* Infiltrating hepatocellular carcinoma: seeing the tree through the forest. *J Gastrointest Surg* 2011; 15: 2089-97.
25. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. *Cancer* 1954; 7: 462-503.
26. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; 53: 1020-2.
27. Lee JM, Choi BI. Hepatocellular nodules in liver cirrhosis: MR evaluation. *Abdom Imaging* 2011; 36: 282-9.
28. Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. *Dig Dis* 2009; 27: 114-24.
29. Bitar R, Leung G, Perng R, *et al.* MR pulse sequences: what every radiologist wants to know but is afraid to ask. *Radiographics* 2006; 26: 513-37.
30. Kang BK, Yu ES, Lee SS, *et al.* Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. *Invest Radiol* 2012; 47: 368-75.
31. Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. *Expert Rev Anticancer Ther* 2010; 10: 507-19.
32. Sun HY, Lee JM, Shin CI, *et al.* Gadoteric acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. *Invest Radiol* 2010; 45: 96-103.
33. Taouli B, Ehman RL, Reeder SB. Advanced MRI methods for assessment of chronic liver disease. *AJR Am J Roentgenol* 2009; 193: 14-27.
34. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. *Radiology* 2010; 254: 47-66.
35. Bartolozzi C, Battaglia V, Bozzi E. HCC diagnosis with liver-specific MRI: close to histopathology. *Dig Dis* 2009; 27: 125-30.
36. Hayashi M, Matsui O, Ueda K, *et al.* Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. *AJR Am J Roentgenol* 1999; 172: 969-76.
37. Choi BI. Hepatocarcinogenesis in liver cirrhosis: imaging diagnosis. *J Korean Med Sci* 1998; 13: 103-16.
38. Han JK, Eun HW, Kim SH. Radiologic findings of dysplastic nodule. *Korean J Hepatol* 2008; 14: 231-4.
39. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. *Radiographics* 2008; 28: 747-69.
40. Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. *Carcinogenesis* 2008; 29: 1299-305.
41. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. *Arch Toxicol* 2013; 87: 227-47.
42. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. *Nat Genet* 2002; 31: 339-46.
43. Ichikawa T, Sano K, Morisaka H. Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. *Liver Cancer* 2014; 3: 97-107.